4 years of financing of more than 2.5 billion, and platinum pharmaceutical to Hong Kong listing! What's the magic of this star venture capital's new drug company?

Guide: New drug research and development companies are widely sought after, venture capital to help.
, hkex in the second half of this year will usher in the IPO of unleanswered pharmaceutical companies carnival feast, has now handed over the star enterprises have Jiahe Bio, Rongchang Biopharmaceuticals, Yunding Xinyao, Pharmaceutical Ming Juno, and platinum medicine is also coming! Source: Gazelle, Zhitong Financial According to the Hong Kong Stock Exchange on August 18 disclosed, and Platinum Pharmaceutical Holdings Limited to the Hong Kong Stock Exchange to submit the main board listing application, Morgan Stanley, BofA Securities and CITIC Securities as co-sponsors. Founded at the end of 2016,
and Platinum Pharma is a clinically developed, global and innovative biopharmaceutical company focused on the development of innovative drugs for tumor immune and immunological diseases, and is committed to providing patients worldwide with innovative drugs in the field of tumor immune and immunological diseases.
it is worth noting that and platinum medicine for the domestic minority with all-human antibody genetically modified mice, one of several biotechnology companies, in addition to the introduction of OMT, Bai Osaitu and so on.
in the development of pipeline layout, and platinum medicine at the same time focus on cancer and autoimmune diseases.
In the dual anti-product line, many pharmaceutical companies take CD3/TAA dual resistance, some pharmaceutical companies such as Tiantian biological focus on 4-1BB/TAA dual resistance, and platinum medicine pipeline at the same time layout CD3/TAA and 4-1BB/CD3 dual resistance.
the magic of the biopharmaceutical company, which has been in business for just over four years, has a post-investment valuation of $780m (RMB5,538m) after completing round C financing in July. Dr. Wang Jinsong, Founder, Chairman and CEO of the Excellent Management Team, is a leading scientist with a Chinese and American background, an amphibious talent in academia and industry, has served as a lecturer at Harvard Medical School, a rheumatologist, and the global program leader of the Parkson Squio Clinical Program.
, he also served as President of Research and Development in China and Head of Translational Medicine asia Pacific at Sanofi, an international super-large pharmaceutical company.
At least half of the current and platinum pharmaceutical teams are scientists with overseas backgrounds, with extensive knowledge of basic sciences such as medicine and biology, as well as outstanding performance in drug development and development.
and Platinum Pharma also have a strong scientific advisory panel of world-class scientists from Europe and the United States who can connect laboratory discoveries to clinical research to explore the frontiers of science and new drug discoveries from a holistic perspective.
, the ability to absorb gold is full, venture capital piles in less than five years, and platinum medicine completed five rounds of financing, the total financing amount of more than 350 million U.S. dollars, the ability to suck gold is strong.
And in its introduction of shareholders, the number of pharmaceutical professional well-known venture capital can be described as "stacking", including Dingyi Capital, Junlian Capital, Shang Capital, Singapore Government Investment, Reliance Capital, Aobo Capital, Gautjia Investment, including Junlian Capital invested in three rounds, Singapore Government Investment monkCapital invested in two rounds, it can be seen that and platinum pharmaceutical bullish.
we believe there will be more faces of new institutions when and Platinum Pharma introduce cornerstone investors in the HKEx IPO.
, pipeline analysis and platinum medicine since its inception is committed to the establishment of a solid immune and tumor immunological new drug research and development pipeline.
already has five new drugs in clinical stage, and its extensive independent research and development of new pipelines and innovative therapies in collaboration with top research institutions and biopharmaceutical companies are also growing rapidly.
Research and development pipeline (photo source: and platinum pharmaceutical company's official website) - HBM9036 (Tenasip): China's dry eye field of the first global new bio-anti-inflammatory drug HBM9036 (HL036) is the whole human-sourced tumor necrosis cause (TNF) receptomy fragments after molecular engineering transformation, with excellent tissue permeability, stability, and strong local TNF and effective protein composition of the liquid eye.
the product has the potential to treat inflammatory eye diseases including dry eyes, irisitis and wet macular degeneration, and is the first new global bio-anti-inflammatory drug in the field of dry eyes in China.
HBM9036 eye drops are the world's new biomass drugs introduced by HBM9036 Eye Drops and Platinum Pharmaceuticals from Han AllBiopharma, Korea, in September 2017, with an interest in clinical development, production and marketing in Greater China.
2018, Heplasma Pharmaceuticals submitted a clinical application to CDE, and in September of the same year, it was officially approved for clinical trials of new drugs.
In October 2019, the company announced that HBM9036 had completed Phase 2 of the Dry Eye Clinical Trial, which met the expected research objectives and was consistent with HanAll's previous Results of The Clinical Phase II Trial (VELOS-1) in the United States;
The global dry eye disease market size of more than 5 billion U.S. dollars, has not yet targeted treatment products due to the aging of the population, the popularity of electronic products led to changes in eye habits and other reasons, as well as glacial eyes, rheumatoid arthritis, LASIK visual surgery complications, the prevalence of dry eye disease increased year by year, China's dry eye disease patients about 75 million people.
The global dry eye market reached $5.04 billion in 2016 and the Chinese dry eye market reached about $146 million in 2018, according to Transparency Market Research and MarketSpace.
.HBM9161: The gospel HBM9161 for primary immunocytocytosis patients is an all-human antibody that targets newborn FcRn, blocking FcRn's IgG interaction to accelerate the degradation of autoantibodies, thus treating a variety of pathogenic IgG-mediated autoimmune diseases such as severe muscle weakness, severe eye disease, optic neuromyelitis spectrum and primary myelitis.
Ingenerative mechanisms based on HBM9161, as well as the highly unmet needs of autoimmune diseases in China, and Platinum Pharma have initiated several phase 2/3 registered clinical studies in China and plan to launch clinical studies this year on autoimmune diseases including severe muscle weakness, thyroid eye disease, and optic neuromyelitis spectrum disease.
In August 2018, Heplastic Pharmaceuticals announced that it had successfully completed the clinical research declaration of HBM9161 injections to the General Administration of Drug and Food Supervision of China, becoming the first biomass innovative drug to be successfully declared and accepted since Order 50 was issued by the General Administration of Drug Administration of China on July 27, 2018.
February 21, 2020, HBM9161 announced that it had successfully completed the Clinical Phase 1 study of HBM9161.
the study, which included Chinese health volunteers, was designed to assess the safety, tolerability, pharmacological dynamics and pharmacetic characteristics of HBM9161.
results show that HBM9161 has good safety and can effectively reduce the level of IgG.
The Phase 2/3 clinical trial of HBM9161 was approved by China's State Drug Administration on April 16, 2020 to assess the safety and effectiveness of its treatment of primary immunocytate reduction, and the approval allows direct access to Phase 3 trials after the first mid-term analysis of Phase 2 trials to accelerate the clinical development of the world's first innovative drug in China.
April 21, 2020, and Platinum Pharmaceuticals announced that Batoclimab (HBM9161) had completed the first patient grouping for a clinical phase 1b/2a study of optic neuromyelitis spectrum disease.
clinical study was conducted to assess the safety, tolerance, pharmacology and efficacy of batoclimab (HBM9161) in patients with optic spinal cord disease in China.
is also the world's first study of anti-FcRn target drugs in the optic neuromyelitis genealogy.
Ingenerative mechanisms based on HBM9161, as well as the highly unmet needs of autoimmune diseases in China, and Platinum Pharmaceuticals plans to launch clinical studies this year on autoimmune diseases including severe muscle weakness, thyroid eye disease, optic neuromyelitis genealogy diseases, and more.
HBM4003: A new generation of all-human anti-CTLA-4 antibody HBM4003 is an all-human anti-CTLA-4 heavy-chain antibody, produced from and platinum medicine unique HarbourMice® platform.
HBM4003 showed strong anti-tumor effects and the potential to significantly reduce drug toxicity in preclinical studies.
HBM4003 showed enhanced antibody-dependent cell-mediated cytotoxicity (ADCC), which is highly specific to CTLA-4 HighTreg cells in tumor tissue.
its strong anti-tumor effects, differentiated pharmacogenic characteristics and long-lasting drug effects exhibit good product characteristics, and this novel and differentiated mechanism of action gives it the potential to improve treatment effectiveness and significantly reduce drug toxicity.
February 28, 2020, HBM4003 was approved by the FDA for a clinical trial of a new drug and will conduct a clinical study in the United States on HBM4003 as a single drug for patients with advanced solid tumors, designed to evaluate the safety, tolerability, pharmacodynamics, and anti-tumor activity of HBM4003.
addition, the HBM4003 trial was launched in Australia in 2019 and the first patient in the trial successfully took the drug in November 2019 and is currently well under way.
HBM9167: The antibody drug HBM9167, which qualifies orphan drugs for nasopharyngeal cancer, is a recombinant humanized IgG1 monoclonal antibody for PD-L1.
By binding to PD-L1, HBM9167 blocks its interaction with PD-1, releasing PD-L1/PD-1-mediated inhibition of the immune response, thereby restoring the cytotoxic immune function of T cells and enhancing the immune system's anti-tumor ability.
monoclonal antibodies targeting PD-1 or PD-L1 can inhibit the binding activity of the two, maintain the function of effect T cells, thus preventing cancer cells from escaping immune surveillance and maintaining the body's immunity to cancer cells.
and Platinum Pharma introduced HBM9167 from Colombota and has the right to develop and commercialize it worldwide, with the exception of Greater China.
February 27, 2020, HBM9167 has been approved by the U.S. FDA for clinical Phase II trials and has been granted orphan drug accreditation for the treatment of nasopharyngeal cancer.
In the product line layout, the company on the one hand to develop new targets, but also do not rule out for some known targets in the clinical unsatisfied needs to improve, on the other hand, the use of its unique HCAb platform to develop innovative structure of next-generation antibody drugs, such as the new generation of CTLA-4 antibody HBM4003, with better anti-tumor activity, and significantly reduce the potential of drug toxicity, from two aspects to expand the treatment window.
addition, and platinum medicine has a number of early development phase of research projects, including: 1) HBM7020, a new dual-specific antibody for BCMA and CD3, contains HCAb immune cell bridger; , containing all-human source IgG1 monoclonal antibodies and soluble extracellular regions of the conversion growth factor beta receptor II (TGFbR2); 4) HBM7008, a new dual-specific antibody for TAA and 4-1BB, contains AbHC Immune Cell Bridger.
, Performance List and Platinum Pharmaceuticals products have not been approved for commercial sale and have not generated any proceeds from the sale of the products.
financial data show that in the past two fiscal years, 2019 and the first half of 2020, and platinum pharmaceutical revenue of $1.483 million, 5.419 million and 6.07 million U.S. dollars, respectively, research and development expenditure of 31.63 million, 4,947 The corresponding net losses of $34.583 million, $67.496 million and $48.382 million, respectively, were concluded: in addition, Platinum Pharma considered co-development on a global scale to be an important core strategic layout.
In addition to the original patent licensing business for technology for the gm mouse platform for platinum medicine to industry and academia, the company has also shifted its focus to biopharmaceutical companies that take full advantage of the strength of independent innovation and complementary resources to jointly develop new drugs.
the company has signed a number of joint research and development programs with partners to expand the pipeline of new drug research and development, and widely authorized and platinum pharmaceutical genetically modified mouse platform to better promote the next generation of new drug innovation research and development.
believe that the future and platinum medicine will become an indispensable player in the domestic antibody industry!